Full clinical trial not needed for Parkinson’s drug patent, IP Australia says
An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.
For information on rights and reprints, contact subscriptions@lawyerly.com.au